Asset
CADISEGLIATIN
VTV THERAPEUTICS INC. CLASS A COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02405260 | phase2 | completed | 2015-03-01 | 2016-07-01 | vTv Therapeutics | Add Glucokinase Activator to Target A1c |
| NCT06334133 | phase3 | active_not_recruiting | 2024-06-14 | 2027-04-01 | vTv Therapeutics | Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes |
| NCT07616206 | phase2 | not_yet_recruiting | 2026-10-01 | 2027-06-01 | vTv Therapeutics | Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) Systems |
| NCT03335371 | phase1_2 | completed | 2017-10-25 | 2019-12-20 | vTv Therapeutics | Evaluation of TTP399 in Patients With Type 1 Diabetes |
FDA applications (0)
This company has no applications containing this asset.